1. Home
  2. SLDB vs AEVA Comparison

SLDB vs AEVA Comparison

Compare SLDB & AEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Solid Biosciences Inc.

SLDB

Solid Biosciences Inc.

SELL

Current Price

$6.43

Market Cap

623.0M

Sector

Health Care

ML Signal

SELL

Logo Aeva Technologies Inc.

AEVA

Aeva Technologies Inc.

SELL

Current Price

$8.81

Market Cap

708.9M

ML Signal

SELL

Company Overview

Basic Information
Metric
SLDB
AEVA
Founded
2013
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Auto Parts:O.E.M.
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
623.0M
708.9M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
SLDB
AEVA
Price
$6.43
$8.81
Analyst Decision
Strong Buy
Buy
Analyst Count
15
5
Target Price
$18.71
★ $24.80
AVG Volume (30 Days)
1.2M
★ 1.8M
Earning Date
11-04-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 34.97
10.53
EPS
★ N/A
N/A
Revenue
★ $8,094,000.00
N/A
Revenue This Year
N/A
$73.43
Revenue Next Year
N/A
$132.18
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$4.65
$8.26
52 Week High
$11.45
$31.30

Technical Indicators

Market Signals
Indicator
SLDB
AEVA
Relative Strength Index (RSI) 46.83 40.20
Support Level $6.25 $9.44
Resistance Level $6.58 $16.49
Average True Range (ATR) 0.50 1.01
MACD 0.02 0.06
Stochastic Oscillator 30.12 25.89

Price Performance

Historical Comparison
SLDB
AEVA

About SLDB Solid Biosciences Inc.

Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.

About AEVA Aeva Technologies Inc.

Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The 4D LiDAR sensors are designed to detect both velocity and position, supporting perception and decision-making in automated systems. The company operates in North America, EMEA, and Asia. The company's revenue consists of sales of perception solutions or sensing systems and non-recurring engineering services. Geographically, it derives the majority of its revenue from North America.

Share on Social Networks: